Close Success Stories Aniling www.aniling.com

Project leader

Llorenç Coll

Start year

2014

Participating organizations

IMPPC

Project aims

Aniling is a company that is working to make precision medicine possible using the epigenomics revolution, developing a new standard for genetic analysis globally, with technology that can analyze the genome and epigenome simultaneously.

Collaboration framework

Aniling was created as a spin-off of the Institute of Predictive and Personalized Medicine of Cancer (IMPPC), through an agreement that granted Aniling the exclusive license to a patent protecting this technology. The founders of the project were Llorenç Coll (CEO) and Miguel Àngel Peinado (CSO), with Jaume Amat as their strategic adviser. The company also has a scientific advisory board with experts like Elías Campo, Manel Esteller, Ivo Gut and Susan Clark.

Most significant challenges

From the beginning, one of Aniling's strategic focal points has been to create a robust, flexible, well-balanced team. Additionally, defining the market was also a challenge in the early stages, given the significant innovative component of the technology. The next phase for Aniling is to take the prototype to market and, to do so, the company is working with international opinion leaders. This requires additional investment to validate the product on the market. The company is currently working to raise more funds, from both public and private sources.

Results

So far, Aniling has invested more than €1 million in developing a prototype for advanced users in the oncology arena. This funding has been obtained from various sources, including Caixa Capital Risc and ACCIÓ. Aniling has recently launched an Advanced User Program internationally. In Catalonia, groups are participating from institutions like ICO, Hospital Clinic, VHIR (AMMIC project under RIS3CAT) and the ADN GCAT-Genomes for Life DNA biobank. In the first phase, roughly 200 samples will be analyzed to validate the market for the company's first kit. According to Aniling, the technology will save time, money and sample size, analyzing the genome and epigenome simultaneously for the first time, increasing sensitivity and reducing error rates 10- to 100-fold over current standards.